Pluripotent stem cell that induces repair and regeneration after myocardial infarction

Patent metadata

Field	Value
Publication number	US-10639335-B2
Application number	US-201916452376-A
Country	US
Kind code	B2
Filing date	Jun 25, 2019
Priority date	Aug 17, 2012
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

First claim

The invention claimed is:

1. A method of treating myocardial infarction in a subject in need thereof, the method comprising: administering to said subject a cell preparation comprising concentrated pluripotent stem cells positive for SSEA-3, wherein the pluripotent stem cells are obtained from a mesenchymal cell population derived from mesenchymal tissue or cultured mesenchymal cells, wherein said pluripotent stem cells have been purified by selecting SSEA-3 positive stem cells or concentrated by external stress stimulation, to thereby treat the myocardial infarction, and wherein the pluripotent stem cells have a plurality of properties comprising: (i) CD105-positivity; (ii) low or absent telomerase activity; (iii) ability to differentiate into embryonic endoderm, ectoderm, and mesoderm germ layers; (iv) absence of demonstration of neoplastic proliferation; and, (v) ability to self-renewal.

2. The method according to claim 1 , wherein the cell preparation contains a cell fraction wherein the pluripotent stem cells positive for SSEA-3 have been concentrated by external stress stimulation.

3. The method according to claim 1 for treatment of heart failure following serious massive myocardial infarction in humans.

4. The method according to claim 1 , wherein the pluripotent stem cells are CD117-negative and CD146-negative.

5. The method according to claim 1 , wherein the pluripotent stem cells are CD117-negative, CD146-negative, NG2-negative, CD34-negative, vWF-negative and CD271-negative.

6. The method according to claim 1 , wherein the pluripotent stem cells are CD34-negative, CD117-negative, CD146-negative, CD271-negative, NG2-negative, vWF-negative, Sox10-negative, Snail-negative, Slug-negative, Tyrp1-negative and Dct-negative.

7. The method according to claim 1 , wherein the pluripotent stem cells have the ability to integrate into the site of myocardial infarction.

8. The method according to claim 1 , wherein the pluripotent stem cells have the ability to differentiate into myocardial cells.

9. The method according to claim 1 , wherein the pluripotent stem cells have the ability to differentiate into vascular endothelial cells.

10. The method according to claim 1 , wherein the pluripotent stem cells are administered into a vein or coronary artery of a subject within 1 month after ischemia one to ten times in a therapeutically effective amount of 1×10 3 cells/individual to 1×10 6 cells/individual.

11. The method according to claim 1 , wherein the size of the myocardial infarction is reduced compared to a control subject not administered the cell preparation.

12. The method according to claim 1 , wherein at least one cardiac function indicator, selected from the group consisting of change in left ventricular pressure over time, left ventricular end-diastolic dimension (LVDd), ejection fraction (EF), left ventricular fractional shortening (FS) and left ventricular end-systolic dimension (LVDs), is restored to the normal value.

13. The method according to claim 1 , wherein the cell preparation is administered into a vein or coronary artery of said subject within 1 month after ischemia in a therapeutically effective amount of 1.7×10 5 cells/kg to 2.5×10 5 cells/kg per individual mammal based on body weight.

Assignees

• Clio Inc
• Univ Gifu
• Univ Tohoku

Inventors

• Yoshida Masanori
• Minatoguchi Shinya
• Dezawa Mari

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• C12N5/0607

  Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696) · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K35/28 Primary

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C12N2506/03

  from non-embryonic pluripotent stem cells · CPC title